Ignite Creation Date:
2025-12-25 @ 4:32 AM
Ignite Modification Date:
2026-02-03 @ 8:25 AM
Study NCT ID:
NCT06063018
Status:
RECRUITING
Last Update Posted:
2023-10-02
First Post:
2023-09-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer
Sponsor:
Organization: